Background: The combination of chemotherapy with radiotherapy serves as a common therapeutic strategy in clinics. However, it is unsatisfactory due to its poor therapeutic efficiency and severe side-effects originating from chemotherapy-exerted systemic toxicity as well as radiation-induced injury. Purpose: Hence, Berberine (Ber), an isoquinolin alkaloid with low toxicity and protective effects against radiotherapy, was used as a novel chemotherapeutic agent for chemo-radiotherapy of liver cancer. Patients and methods: We preloaded Ber into folic acid targeting Janus gold mesoporous silica nanocarriers (FA-JGMSNs) for overcoming the poor bioavailability of Ber. Furthermore, FA-JGMSNs were not only employed as radiosensitizers for expanding radiotherapeutic effect, but also used as photothermal agents for supplementing chemo-radiotherapeutic effect by local photothermal therapy. Results: In vitro and in vivo experiemtal results demonstrated the highly efficient antitumor effect, good biosafety as well as the effective protection of normal tissue of this nanoplatform. Conclusion: Based on its superb performance, we believe our work provided a feasible strategy for triple-therapies of liver cancer.
Introduction
Liver cancer is considered to be one of the most common and formidable diseases. [1] [2] [3] Chemotherapy and radiotherapy (RT) are standard therapeutic methods in clinic and the combination of chemotherapy with radiotherapy has been demonstrated to exert a synergistic anti-tumor effect. 4, 5 However, this combined chemo-radiotherapy in clinic is unsatisfactory due to its severe side-effects and limited therapeutic outcomes. [6] [7] [8] During RT, ionization radiation inevitably passes through peritumoral normal tissues, generating a series of side-effects. 9 Chemotherapeutic drugs further aggravate the adverse effects due to their highly systemic toxicities and the lack of specificity. 10, 11 In addition, multi-drug resistance and radio-resistance also limit the outcomes of chemo-radiotherapy. 12 Hence, it is urgent to develop new chemo-radiotherapeutic strategies for highly efficient and safe treatment of liver cancer.
Berberine (Ber), an isoquinolin alkaloid isolated from natural herbs, has exhibited a remarkable anticancer activity in recent researches. 13, 14 More importantly, Ber possesses fewer side-effects and resistance compared with traditional chemotherapeutic drugs and can significantly reduce radiationinduced organic injury. [15] [16] [17] Hence, Ber combined with RT would surmount the severe side-effects of chemoradiotherapy. However, the application of Ber is limited because of its poor aqueous solubility, leading to reduced bioavailability. [18] [19] [20] Moreover, this chemo-radiotherapy is insufficient to eradicate tumor tissues. Utilizing high-Z nanomaterials as radiosensitizers can effectively impove ionizing radiation delivery in the tumor site and achieve a higher radiotherapeutic outcome. [21] [22] [23] Additionally, employing photothermal therapy (PTT) as an adjuvant treatment of chemoradiotherapy has also attracted great attention owing to the safe therapeutic modality of PTT and its excellent capacity to potentiate chemotherapeutic and radiotherapeutic effects by influencing cancer cell metabolism and changing the microenvironment of tumor. [24] [25] [26] [27] Thus, the integration of Ber therapy, radiotherapy sensitization and PTT would be a feasible method for simultaneously achieving a powerful therapeutic effect and low side-effects as well as a protective effect to normal tissues. However, it still remains challenging to seek a proper agent for synchronously driving the triple-modal therapies.
The thriving nanotechnology field has brought out new opportunities for highly efficient, specific and personalized cancer theranostics. [28] [29] [30] Among them, gold-based nanoplatforms have drawn great attentions because of their outstanding properties and applications such as tunable surface plasmon resonance properties for PTT, strong X-ray attenuation for computed tomography(CT) imaging contrasts as well as high Z number for radiotherapy sensitization. [31] [32] [33] Recently, gold mesoporous silica nanomaterials exhibited superior advantages on cancer multimodel therapies owing to their good biocompatibilities, high surface area, easily modified surface as well as multiple physical and chemical properties. [34] [35] [36] Our group previously designed uniform Janus gold mesoporous silica nanocarriers (JGMSNs). These JGMSNs have been demonstrated to be not only superior radiosensitizers and CT imaging contrasts for CT imaging-mediated radiotherapy, but also intriguing drug vehicles because of their strong drug loading capacity and responsive drug release properties. 37 Additionally, JGMSNs also show high photothermal conversion efficiency as photothermal agents for local PTT. More importantly, the asymmetric structure of , these mice were randomly divided into eights groups (n=3/group). PBS, FA-JGMSNs (20 mg/kg), JGMSNs-Ber (25 mg/kg) and FA-JGMSNs-Ber (25 mg/kg) were intravenously injected and free Ber (5 mg/kg) was intraperitoneally injected into the mice every 3 days. In X-ray irradiation groups, 1 Gy/min of X-ray radiation with a 1.5 cm×1.5 cm radiation field was used to irradiate the entire tumor for 5 minutes after 1 day of post-injections. In NIR irradiation groups, these tumor sites of the mice were exposed under an 808 nm laser (1 Wcm 
The protective effect against radiation-induced intestinal injury
Approximately 20 g of nude mice bearing SMMC-7721 xenograft were randomized into five groups and treated with PBS, free Ber (5 mg/kg), FA-JGMSN (20 mg/kg) and FA-JGMSNs-Ber (25 mg/kg) every 3 days. Then, 1 Gy/ min of X-ray radiation was used to irradiate the entire tumor for 0, 5, 10 minutes after 1 day of post-injections. After 3 times RT, the body weight and the average intake of food were measured. Then, the serum was collected and intestinal fatty acid-binding protein (iFABP), and diamine oxidase (DAO) were measured by an assay kit.
Statistical analyses
All the data represented three separate experiments and presented as the mean ± SD. The different groups were analyzed by a one-way analysis of variance. Bonferroni post hoc test was implemented for the analyses of different groups. P<0.05 represented a statistically significant difference.
Results and discussions
JGMSNs were synthesized by a modified sol−gel method as previous reports. 44 As shown in Figure 1A , JGMSNs exhibited an asymmetric structure, which consist of a gold nanorod with dimensions of 50-60/10-15 nm and a silica stick with dimensions of 200-250/100-120 nm. To improve the stability of these JGMSNs and endow them with liver cancer-targeting capability, JGMSNs was functionalized by carboxyl groups and then FA-PEG was conjugated on the surface of JGMSNs to form FA-JGMSNs. The FT-IR spectra in Figure S1 exhibited that the characteristic adsorption peaks of FA-PEG-NH 2 at 1335 −1 and 1100 cm −1 appeared in the FA-JGMSNs group, while a new adsorption peaks of the amide carbonyl groups at 1640 −1 and 1540 cm −1 were also observed in the FAJGMSNs group, demonstrating that FA was conjugated on the surface of these nanoparticles. Furthermore, The UV−visible spectra in Figure 1B showed an absorption peak of approximately 280 nm which was consistent with the characteristic absorption peak of FA was located in the FA-JGMSNs, also confirming the successful conjugation of the FA. Additionally, FA-JGMSNs possessed an absorption peak of 740 nm, which was a slight red shift in comparison to that of Au rods, suggesting that the FAJGMSNs preserved the optical properties of Au rods. Furthermore, the particle sizes of FA-JGMSNs remained constant for 5 days, whereas JGMSNs aggregated, suggesting that PEGylation process improved the long-term stability of JGMSNs ( Figure S2 ). Then, we investigated the mesoporous structure of FA-JGMSNs by BET method and BJH method. The N2 adsorption−desorption isotherms in Figure 1C showed type IV curves, confirming the existence of mesopores. The average mesopore size of FAJGMSNs was 2.2 nm ( Figure S3 ), and its BET surface area and total pore volume were 723.6 m 2 /g and 0.46 cm 3 /g, respectively. The excellent mesoporous properties of FAJGMSNs indicated their high Ber loading capacity. For Ber loading, we dissolved Ber into dimethyl sulphoxide (DMSO) for increasing its solubility. Then, Ber was preloaded into the silica body of FA-JGMSNs via the charge interaction. Figure S4 showed the Zeta potentials of +23.2, −14.2, −16.2, 5.9, −22.8, −10.9 and +4.7 mV, for Au nanorods, JGMSNs, JGMSNs (CTAB free), JGMSNs-NH 2 , JGMSNs -COOH, FA-JGMSNs and FA-JGMSNsBer respectively. The Ber loading efficiency and the Ber loading content on JGMSNs were respectively 47.4% and 19.1%. These FA-JGMSNs-Ber exhibited no obvious change in size and PDI ( Figure S5 ) after 1-week storage period in water. Then, we investigated the Ber release behavior of Ber-loaded FA-JGMSNs (FA-JGMSNs-Ber) in PBS at different pH values (7.4 and 5.5). As shown in Figure 1D , JGMSNs-Ber exhibited a pH-responsive drug release fashion. The cumulative content of releasing Ber was less than 7% at pH 7.4 after 96 hours, whereas 50% of Ber was released after 96 hours at pH 5.5. This pHresponsive Ber release property, which resulted from the protonation and dissociation in acidic environments, was favorable for Ber release in tumor tissues rather than normal tissues since both the microenvironments of extracellular tumor tissue and intracellular endo/lysosomes were acidic.
To verify the FA-targeting capacity of FA-JGMSNs on liver cancer cells, JGMSNs and FA-JGMSNs were respectively labeled with the fluorescence marker FITC and their cellular internalization were quantified by flow cytometry. As shown in Figure 2A , the fluorescence intensity in FA-JGMSNs -treated group was significantly higher than that in JGMSNstreated group in FA receptor-positive SMMC-7721 cells. Moreover, preincubating free FA could effectively reduce the fluorescence sign of FA-JGMSNs due to the competitive blocking of the FA receptor. On the contrary, FA-JGMSNs and JGMSNs showed similar cellular internalization in the HL-7702 cells and both of their uptake in HL-7702 cells were lower than that in SMMC-7721 cells. Additionally, there was could still be detected in both the FA-JGMSNs-Ber-treated group and the JGMSNs-Ber-treated group after 12 hours efflux, indicating these nanocarriers could increase Ber retention in cancer cells. The FA-JGMSNs could effectively surmount the chemotherapeutic resistance of pump efflux, which contributed to further improving the chemotherapeutic effect.
To verify the therapeutic effect of FA-JGMSNs-Ber, SMMC-7721 cells and HL-7702 cells were co-incubated with JGMSNs, FA-JGMSNs, free Ber, JGMSNs-Ber or FA-JGMSNs-Ber for 24 hours and their cytotoxicity was measured by SRB assay. As illustrated in Figure 3A and B, the cell viability was still above 90% in the FA-JGMSNstreated group or the JGMSNs-treated group when the concentration of nanoparticles reached 10 μg/mL, indicating that these nanocarriers possessed excellent biocompatibility. Free Ber, JGMSNs-Ber and FA-JGMSNs-Ber all exhibited the dose-dependent cytotoxicity towards SMMC-7721 cells and HL-7702 cells. JGMSNs-Ber killed more SMMC-7721 cells than the equal dose of free Ber and FA-JGMSNs-Ber showed the best anti-cancer effect. Conversely, more HL-7702 cells lived when treated with JGMSNs-Ber or FA-JGMSNs-Ber compared with those treated with free Ber. The selective kill effect was consistent with Ber intracellular distributions. Encouraged by the excellent chemotherapeutic effect of FA-JGMSNs-Ber, we further investigated the combined chemo-radiotherapeutic effect based on FA-JGMSNs-Ber. As illustrated in Figure  3C , the radiotherapeutic effect to SMMC-7721 cells was substantially improved after being treated with FAJGMSNs or JGMSNs compared with those without any treatment of nanoparticles, demonstrating the radiosensitization of these nanoparticles, which was in line with our previous reports. 31 Additionally, JGMSNs-Ber with X-ray irradiation killed more SMMC-7721 cells than either JGMSNs-Ber without RT or JGMSNs with RT and FA-JGMSNs-Ber with RT showed better therapeutic effect than JGMSNs-Ber with RT. Some reports have revealed that the combination of chemotherapy with RT could exert excellent synergistic therapeutic effect because chemotherapy could effectively inhibit the repair of radiation-induced DNA damage as well as arrest cell cycle in the radiosensitive G2/M phase. 47, 48 Moreover, the combination of chemotherapy with RT could lead to an endoplasmic reticulum stress in tumor tissues, which induced the autophagy and apoptosis of cancer cells and the release of ATP and high mobility group box 1 (HMGB1) as well as the intratumoral accumulation of dendritic cells, γδ T cells and CD8+ T lymphocytes, resulting in an immune response for enduring the powerful anti-tumor effect. 49 Our results confirmed the high efficiency of chemoradiotherapy by FA-JGMSNs-Ber, which were consistent with previously reported applications of nanoparticles for combined chemoradiotherapy. 50, 51 Notably, FA-JGMSNsBer combining with RT didn't obviously increase the mortality of HL-7702 cells compared with RT ( Figure  3D ). It was due to the weak uptake of FA-JGMSNs-Ber and selective response Ber release as well as the low toxicity of Ber. For further expanding the anti-tumor effect, PTT was combined with chemo-radiotherapy. We firstly explored the photothermal conversion efficiency of FA-JGMSNs-Ber in culture medium. As shown in Figure S6 , only a 5°C increase was measured in pure water and free Ber solution as well as the cell medium under the near infrared (NIR) irradiation, whereas the temperature increases of FAJGMSNs-Ber solution exhibited a time-and concentrationdependent fashion. The temperature reached 43°C when the concentration of FA-JGMSNs-Ber was 12.5 μg/mL under the NIR irradiation of less than 5 minutes, which was up to the criteria of inducing cancer cells death. Then, we explored the localized photothermal effect and evaluated the triple-model therapies in vitro. As shown in Figure  3C , the viability of SMMC-7721 cells only under NIR irradiation without any treatment was reduced by <5%, indicating the NIR irradiation was safe for the SMMC7721 cells. When pre-treated with JGMSNs or FAJGMSNs, the NIR irradiation led to a substantial toxicity towards SMMC7721 cells, demonstrating the effectiveness of PTT by these nanoparticles. Interestingly, the NIR irradiation combining with X-ray irradiation caused more deaths of cells than either NIR irradiation or X-ray irradiation after treatment with JGMSNs or FA-JGMSNs.
Additionally, JGMSNs-Ber or FA-JGMSNs-Ber with NIR irradiation showed stronger killing effects in comparison to those without NIR irradiation. These results indicated the anticancer effects of the combination treatment of RT with PTT or chemotherapy with PTT were better than single PTT, RT or chemotherapy. As we expected, triple-model therapies based on FA-JGMSNs-Ber exhibited the best therapeutic effect. The synergistic effect probably originated from the increased temperatures improving the sensitivity of the cancer cells to RT and chemotherapy. Furthermore, over 90% of HL-7702 cells survived after treatment with nanoparticles under NIR owing to the better hyperthermia tolerance of normal cells in Figure 3D . Notably, chemo/ radio/photothermal therapeutics didn't cause the amounts of deaths of HL-7702 cells, indicating an excellent biosafety of the triple-model therapy.
To further verify the triple-model therapy in vivo, nude mice SMMC-7721 xenograft models were established. Then, PBS, free Ber, FA-JGMSNs, JGMSNs-Ber and FAJGMSNs-Ber were respectively administered into the mice every 3 days. In X-ray irradiation groups (RT, FAJGMSNs + RT, FA-JGMSNs-Ber + RT, JGMSNs-Ber + RT + NIR, FA-JGMSNs-Ber + RT+NIR), the mice received 5 Gy of X-ray radiation. In the NIR irradiation groups (JGMSNs-Ber + RT + NIR, FA-JGMSNs-Ber + RT + NIR), the tumor sites were exposed under an 808 nm laser for 5 minutes. As illustrated in Figure 4A -C, free Ber couldn't inhibit tumor growth compared with the PBS group due to its poor bioavailability. FA-JGMSNs-Ber exhibited a substantial anti-tumor effect, indicating that FA-JGMSNs were effective nanocarriers for improving therapeutic effect of Ber. Additionally, FA-JGMSNs + RT performed better than RT, demonstrating that FAJGMSNs were also effective radiosensitizers. Furthermore, FA-JGMSNs-Ber combining with RT displayed higher tumor inhibition rates than FA-JGMSNsBer or FA-JGMSNs with RT, confirming the combined effect by FA-JGMSNs-Ber. As we expected, when NIR was administrated, the therapeutic efficiency of FAJGMSNs-Ber with RT were remarkably enhanced. Moreover, FA-JGMSNs-Ber + RT + NIR showed the higher level of tumor-growth inhibition than JGMSNsBer + RT + NIR. These findings revealed the excellent anti-tumor effect of the triple-model therapy by FAJGMSNs-Ber. To further detect the systemic toxicity of FA-JGMSNs-Ber, we measured the blood chemistry indexes (liver function indexes: ALT, AST and kidney function indexes: CRE, BUN) after various treatments.
As illustrated in Figure 5A -D, the levels of ALT, AST, CRE, and BUN were not significantly changed in all the groups compared with control groups. The good liver and kidney functions indicated an excellent biosafety of FAJGMSNs-Ber.
Radiation-induced intestinal injury is a severe clinical problem in patients after RT. The protective efficacy of Ber against radiation-induced intestinal injury has been demonstrated by several studies. 52, 53 Based on the higher bioavailability of FA-JGMSNs-Ber, we deemed that FAJGMSNs-Ber could preferably attenuate the radiationinduced intestinal syndrome. To validate our hypothesis, we administrated the fractionated X-ray irradiation to the xenografts of nude mice bearing SMMC-7721 cells after treatments with PBS, FA-JGMSNs, free Ber or FAJGMSNs-Ber. After courses of treatment, we detected the body weight and food intake of these mice. As shown in Figure 6A and B, the decrease of body weights and average chow intake showed radiation dose-dependent in RT groups and FA-JGMSNs+RT groups. When treated with free Ber, the decrease of body weights and average chow intake were relieved. More importantly, there was no observable body weight losses or chow intake decrease in the FA-JGMSNs-Ber + RT groups compared with the PBS-treated groups, which was better performance than that in free Ber groups. These results demonstrated that FA-JGMSNs-Ber possessed excellent capacities to maintain the body weight and food intake of the mice receiving RT. Furthermore, we detected the level of iFABP and DAO in the plasmid to evaluate the early phases of intestinal mucosal injury of these mice. As shown in Figure 6C and D, the levels of iFABP and DAO in the plasmid were very low without RT because iFABP and DAO were limited in the intestine site. After the X-ray irradiation, the level of iFABP and DAO in the PBS-treated, FAJGMSNs-treated and Ber-treated groups increased with the improving of radiation dose, which was due to the damage of intestinal mucosal by RT. Furthermore, Ber significantly delayed the increasing of iFABP and DAO. Encouragingly, FA-JGMSNs-Ber group exhibited the lower level of iFABP and DAO compared with the free Ber groups. These findings indicated that FA-JGMSNs-Ber possessed an excellent efficacy to reduce radiation-induced intestinal mucosal injury triggered by RT.
Conclusion
In summary, an FA-targeting Janus gold mesoporous silica nanocarriers (FA-JGMSNs) were fabricated to preload Ber for chemo-radio-photothermal therapy of liver cancer. On one hand, FA-JGMSNs showed a high Ber loading capacity and a tumor microenvironment-responsive Ber release behavior as well as a prolonged Ber intracellular retention, thus improving the bioavailability of Ber and expanding its therapeutic efficiency. On the other hand, FA-JGMSNs were developed as dual-functional agents for radiation sensitization and photothermal therapy. FA-JGMSNs-Ber showed excellent anti-tumor efficacy of combination therapies with less side-effects in in-vitro and in-vivo experiments. More importantly, FA-JGMSNs-Ber effectively relieved radiation-induced intestinal injury. Hence, we believed that FA-JGMSNs-Ber integrating highly efficient treatment of cancer tissue with the protection of normal tissue would be a promising candidate for multidimensional therapies of liver cancer.
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